In 2019, the FDA granted the approval of T-Dxd for patients with HER2+ metastatic BC who had received two prior lines of anti-HER2-based therapy in the metastatic setting, based on the results of the DESTINY-Breast 03 trial (NCT0352910). The gene discussed is ERBB2; the disease is breast cancer.